• Consensus Rating: N/A
  • Consensus Price Target: $20.00
  • Forecasted Upside: 98.22 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$10.09
▲ +0.05 (0.50%)

This chart shows the closing price for CELC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Celcuity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CELC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CELC

Analyst Price Target is $20.00
▲ +98.22% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Celcuity in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 98.22% upside from the last price of $10.09.

This chart shows the closing price for CELC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Celcuity. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2022Craig HallumLower TargetNA$30.00 ➝ $20.00High
9/7/2021Jefferies Financial GroupInitiated CoverageBuy$48.00Medium
8/10/2021Needham & Company LLCInitiated CoverageBuy$50.00High
7/29/2021CowenInitiated CoverageOutperformHigh
7/27/2021Needham & Company LLCInitiated CoverageBuy$50.00High
4/12/2021HC WainwrightBoost TargetBuy$19.00 ➝ $30.00High
2/17/2021Craig HallumBoost TargetBuy$19.00 ➝ $24.00Low
2/17/2021HC WainwrightReiterated RatingBuy$18.00 ➝ $19.00Low
1/28/2021HC WainwrightBoost TargetBuy$14.00 ➝ $18.00High
12/24/2020Craig HallumBoost TargetBuy$16.00 ➝ $19.00N/A
12/24/2020HC WainwrightBoost TargetBuy$11.00 ➝ $14.00N/A
8/11/2020HC WainwrightReiterated RatingBuy$11.00Low
7/14/2020HC WainwrightReiterated RatingBuy$11.00Low
6/23/2020HC WainwrightReiterated RatingBuy$11.00High
5/11/2020Craig HallumInitiated CoverageBuyHigh
5/8/2020HC WainwrightReiterated RatingBuy$19.00 ➝ $11.00High
3/13/2020HC WainwrightReiterated RatingBuy$36.00 ➝ $19.00High
12/13/2019HC WainwrightReiterated RatingBuy$36.00Low
5/8/2019HC WainwrightSet TargetBuy$36.00High
12/10/2018HC WainwrightSet TargetBuy$36.00High
11/26/2018HC WainwrightSet TargetBuy$36.00Low
11/20/2018HC WainwrightInitiated CoverageBuy ➝ Buy$36.00Low
11/14/2018Craig HallumBoost TargetBuy$30.00 ➝ $35.00High
10/16/2017Craig HallumInitiated CoverageBuyN/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

1.16 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/5/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 6 very negative mentions
8/4/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/3/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Celcuity logo
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $10.09
Low: $9.71
High: $10.37

50 Day Range

MA: $9.47
Low: $8.00
High: $10.64

52 Week Range

Now: $10.09
Low: $4.81
High: $19.93

Volume

19,911 shs

Average Volume

64,209 shs

Market Capitalization

$150.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Celcuity?

The following Wall Street analysts have issued research reports on Celcuity in the last year: Craig Hallum.
View the latest analyst ratings for CELC.

What is the current price target for Celcuity?

1 Wall Street analysts have set twelve-month price targets for Celcuity in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 98.2%. Craig Hallum has the highest price target set, predicting CELC will reach $20.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $20.00 for Celcuity in the next year.
View the latest price targets for CELC.

What is the current consensus analyst rating for Celcuity?

Celcuity currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CELC.

What other companies compete with Celcuity?

Other companies that are similar to Celcuity include Personalis, Akumin, DermTech, Enzo Biochem and MDxHealth. Learn More about companies similar to Celcuity.

How do I contact Celcuity's investor relations team?

Celcuity's physical mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The company's listed phone number is (763) 392-0767. The official website for Celcuity is www.celcuity.com. Learn More about contacing Celcuity investor relations.